Study summary
Treating myeloma before it becomes active cut the risk of progression in half
63.1%progression-free at 5 years, vs 40.8% with monitoring
What was tested
Daratumumab, against watching and waiting, for high-risk smoldering myeloma, a precursor condition with no approved treatment.
What they found
- Risk of progression to active myeloma or death was 51% lower with daratumumab.
- 93.0% vs 86.9% were alive at 5 years.
What it means
Raises the question of whether some precursor myeloma should be treated before it causes damage, not just watched.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.